137 related articles for article (PubMed ID: 27033222)
41. CD8-positive lymphocytes in graft-versus-host disease of humanized NOD.Cg-Prkdc(scid)Il2rg(tm1Wjl)/SzJ mice.
Laing ST; Griffey SM; Moreno ME; Stoddart CA
J Comp Pathol; 2015; 152(2-3):238-42. PubMed ID: 25670669
[TBL] [Abstract][Full Text] [Related]
42. Safety analysis of ex vivo-expanded canine natural killer cells in a xenogeneic mouse model of graft-versus-host disease.
Kim CJ; Park SC; Lee SH; Lim YJ; Yoon M; Park JG; Baek YB; Cho KO; Hong JW; Shin DJ; Kim SK
J Leukoc Biol; 2022 Feb; 111(2):439-450. PubMed ID: 33884654
[TBL] [Abstract][Full Text] [Related]
43. Delayed onset of graft-versus-host disease in immunodeficent human leucocyte antigen-DQ8 transgenic, murine major histocompatibility complex class II-deficient mice repopulated by human peripheral blood mononuclear cells.
Büchner SM; Sliva K; Bonig H; Völker I; Waibler Z; Kirberg J; Schnierle BS
Clin Exp Immunol; 2013 Aug; 173(2):355-64. PubMed ID: 23607364
[TBL] [Abstract][Full Text] [Related]
44. Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity.
Askenasy N; Mizrahi K; Ash S; Askenasy EM; Yaniv I; Stein J
Biol Blood Marrow Transplant; 2013 Feb; 19(2):185-95. PubMed ID: 23078782
[TBL] [Abstract][Full Text] [Related]
45. Frequent detection of herpes simplex virus antigen in skin and peripheral blood CD34+ mononuclear cells from patients with graft-versus-host disease.
Akpek G; Joseph R; Günay C; Kessler II; Shvartsbeyn M; Bhatnagar B; Aurelian L
Biol Blood Marrow Transplant; 2013 Apr; 19(4):529-37. PubMed ID: 23313704
[TBL] [Abstract][Full Text] [Related]
46. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
47. Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells.
Vendramin A; Gimondi S; Bermema A; Longoni P; Rizzitano S; Corradini P; Carniti C
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2049-55. PubMed ID: 25246295
[TBL] [Abstract][Full Text] [Related]
48. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.
Mevorach D; Zuckerman T; Reiner I; Shimoni A; Samuel S; Nagler A; Rowe JM; Or R
Biol Blood Marrow Transplant; 2014 Jan; 20(1):58-65. PubMed ID: 24140121
[TBL] [Abstract][Full Text] [Related]
49. T lymphocytes determine the development of xeno GVHD and of human hemopoiesis in NOD/SCID mice following human umbilical cord blood transplantation.
Verlinden SF; Mulder AH; de Leeuw JP; van Bekkum DW
Stem Cells; 1998; 16 Suppl 1():205-17. PubMed ID: 11012164
[TBL] [Abstract][Full Text] [Related]
50. Preemptive administration of human αβ T cell receptor-targeting monoclonal antibody GZ-αβTCR potently abrogates aggressive graft-versus-host disease in vivo.
Blank G; Welker C; Sipos B; Sonntag K; Müller F; Eckert F; Seitz C; Nadalin S; LaCorcia G; Königsrainer A; Snell D; Handgretinger R; Schilbach K
Ann Hematol; 2015 Nov; 94(11):1907-19. PubMed ID: 26264693
[TBL] [Abstract][Full Text] [Related]
51. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
52. Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
Chen X; Chang CH; Stein R; Cardillo TM; Gold DV; Goldenberg DM
Biol Blood Marrow Transplant; 2013 Jan; 19(1):28-39. PubMed ID: 23025988
[TBL] [Abstract][Full Text] [Related]
53. Placenta-derived mesenchymal stem cells have an immunomodulatory effect that can control acute graft-versus-host disease in mice.
Jang MJ; Kim HS; Lee HG; Kim GJ; Jeon HG; Shin HS; Chang SK; Hur GH; Chong SY; Oh D; Chung HM
Acta Haematol; 2013; 129(4):197-206. PubMed ID: 23257958
[TBL] [Abstract][Full Text] [Related]
54. Animal models of acute and chronic graft-versus-host disease.
Hakim F; Fowler DH; Shearer GM; Gress RE
Curr Protoc Immunol; 2001 May; Chapter 4():Unit 4.3. PubMed ID: 18432794
[TBL] [Abstract][Full Text] [Related]
55. Immunobiology of allogeneic hematopoietic stem cell transplantation.
Welniak LA; Blazar BR; Murphy WJ
Annu Rev Immunol; 2007; 25():139-70. PubMed ID: 17129175
[TBL] [Abstract][Full Text] [Related]
56. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
Yang K; Fan ZP; Liu QF; Zhang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
[TBL] [Abstract][Full Text] [Related]
57. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
58. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
59. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease.
Tisato V; Naresh K; Girdlestone J; Navarrete C; Dazzi F
Leukemia; 2007 Sep; 21(9):1992-9. PubMed ID: 17625609
[TBL] [Abstract][Full Text] [Related]
60. Donor and host B cell-derived IL-10 contributes to suppression of graft-versus-host disease.
Weber M; Stein P; Prüfer S; Rudolph B; Kreft A; Schmitt E; Bopp T; Roers A; Schild H; Fillatreau S; Radsak MP
Eur J Immunol; 2014 Jun; 44(6):1857-65. PubMed ID: 24643745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
